Induction of multiple drug resistance in HMEC-I endothelial cells after long-term exposure to sunitinib

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 2249-2255

  Huang, Limin ^a   Hu, Chaoquan ^b   Di Benedetto, Mélanie ^c   Varin, Rémi ^d   Liu, Jielin ^b,c   Wang, Li ^c   Vannier, Jean Pierre ^d   Jin, Jian ^c,e   Janin, Anne ^c,f,g   Lu, He ^c,f   Li, Hong ^d  

^a People's Hospital of Guizhou Province   (China)

^b GUIZHOU MEDICAL UNIVERSITY   (China)

^c INSERM   (France)

^d UNIVERSITÉ DE ROUEN   (France)

^e JIANGNAN UNIVERSITY   (China)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g SAINT LOUIS HOSPITAL   (France)

Author keywords

ABC family; Cancer therapy; Drug resistance; Endothelial cells; Sunitinib

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; DOXORUBICIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; SUNITINIB; VINBLASTINE;

ARTICLE; CAPILLARY ENDOTHELIAL CELL; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIDRUG RESISTANCE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; UPREGULATION; WESTERN BLOTTING;

EID: 84919331812     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S67251     Document Type: Article

References (27)

1. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391–400.
2. Young RJ, Reed MW. Anti-angiogenic therapy: concept to clinic. Microcirculation. 2012;19(2):115–125.
3. Eckstein N, Röper L, Haas B, et al. Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective. J Exp Clin Cancer Res. 2014;33:15.
4. Engelman JA, Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev. 2008;18:73–79.
5. Giuliano S, Pagès G. Mechanisms of resistance to anti-angiogenesis therapies. Biochimie. 2013;95(6):1110–1119.
6. Rini BI. Sunitinib. Expert Opin Pharmacother. 2007;8(14):2359–2369.
7. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592–603.
8. Bracci R, Maccaroni E, Cascinu S. Transient sunitinib resistance in gastrointestinal stromal tumors. N Engl J Med. 2013;368(21):2042–2043.
9. Shukla S, Robey RW, Bates SE, Ambudkar SV. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos. 2009;37(2):359–365.
10. Dai CL, Liang YJ, Wang YS, et al. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett. 2009;279(1):74–83.
11. Pénzváltó Z, Tegze B, Szász AM, et al. Identifying resistance mechanisms against five tyrosine kinase inhibitors targeting the ERBB/RAS pathway in 45 cancer cell lines. PLoS One. 2013;8(3):e59503.
12. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays. 1991;13:31–36.
13. Akiyama K, Ohga N, Hida Y, et al. Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment. Am J Pathol. 2012;180:1283–1293.
14. Huang L, Perrault C, Coelho-Martins J, et al. Induction of acquired drug resistance in endothelial cells and its involvement in anticancer therapy. J Hematol Oncol. 2013;6(1):49.
15. Trochon-Joseph V, Martel-Renoir D, Mir LM, et al. Evidence of anti-angiogenic and antimetastatic activities of the recombinant disintegrin domain of metargidin. Cancer Res. 2004;64(6):2062–2069.
16. Ji BS, He L, Liu GQ. Reversal of p-glycoprotein-mediated multidrug resistance by CJX1, an amlodipine derivative, in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Life Sci. 2005;77:2221–2232.
17. Baker EK, Johnstone RW, Zaleberg JR, El-Osta A. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene. 2005;24(54):8061–8075.
18. To KK, Polgar O, Huff LM, Morisaki K, Bates SE. Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells. Mol Cancer Res. 2008;6(1):151–164.
19. Brózik A, Hegedüs C, Erdei Z, et al. Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance? Expert Opin Drug Metab Toxicol. 2011;7(5):623–642.
20. Zhou Q, Lv H, Mazloom AR, Xu H, Ma'ayan A, Gallo JM. Activation of alternate prosurvival pathways accounts for acquired sunitinib resistance in U87MG glioma xenografts. J Pharmacol Exp Ther. 2012;343(2):509–519.
21. Rosenzweig SA. Acquired resistance to drugs targeting receptor tyrosine kinases. Biochem Pharmacol. 2012;83(8):1041–1048.
22. Huang M, Shen A, Ding J, Geng M. Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol Sci. 2014;35(1):41–50.
23. Yang J, Ikezoe T, Nishioka C, et al. Long-term exposure of gastrointestinal stromal tumor cells to sunitinib induces epigenetic silencing of the PTEN gene. Int J Cancer. 2012;130(4):959–966.
24. Piscazzi A, Costantino E, Maddalena F, et al. Activation of the RAS/ RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. J. Clin Endocrinol Metab. 2012;97(6): E898–E906.
25. Shojaei F, Lee JH, Simmons BH, et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res. 2010;70(24):10090–10100.
26. Welti JC, Gourlaouen M, Powles T, et al. Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene. 2011; 30(10):1183–1193.
27. Hida K, Akiyama K, Ohga N, Maishi N, Hida Y. Tumour endothelial cells acquire drug resistance in a tumour microenvironment. J Biochem. 2013;153(3):243–249.